News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

AEterna Laboratories: Research Results Confirm Additional Mechanism of Action of its Lead Compound, Neovastat/AE-941 (PR Newswire)AEterna Laboratories Inc., today announced new results showing that its lead product, Neovastat/AE-941, specifically activates apoptosis of endothelial cells. Previous research had also shown that Neovastat has two other mechanisms of action inhibiting matrix metalloproteinases and Vascular Endothelial Growth Factor, all aimed at stopping a cancerous tumor`s growth, by blocking the formation of new blood vessels.- Mar 27 7:31 AM ET


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010327/mo050.html


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740